Crossref
ESM1 Enhances H3K9 Lactylation-Mediated GPRC5A Transcription to Induce mTOR Pathway Activation and Cisplatin Resistance in Ovarian Cancer
Oncology Research · 2026 · 1-10
DOI: 10.32604/or.2026.084046 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research, 2026. Verfasst von Tian Zeng und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Zeng, T., Luo, Q., Yang, L., Hou, F., Zhao, Y., Liu, X., Jiang, N., Zou, J., & Li, Y. (2026). ESM1 Enhances H3K9 Lactylation-Mediated GPRC5A Transcription to Induce mTOR Pathway Activation and Cisplatin Resistance in Ovarian Cancer. Oncology Research, 0(0), 1-10. https://doi.org/10.32604/or.2026.084046
Vancouver
Zeng T, Luo Q, Yang L, Hou F, Zhao Y, Liu X, et al. ESM1 Enhances H3K9 Lactylation-Mediated GPRC5A Transcription to Induce mTOR Pathway Activation and Cisplatin Resistance in Ovarian Cancer. Oncology Research. 2026;0(0):1-10. doi:10.32604/or.2026.084046
BibTeX
@article{Zeng2026,
author = {Zeng, Tian and Luo, Qingxi and Yang, Li and Hou, Feifan and Zhao, Yongqi and Liu, Xueru and Jiang, Ni and Zou, Juan and Li, Yukun},
title = {ESM1 Enhances H3K9 Lactylation-Mediated GPRC5A Transcription to Induce mTOR Pathway Activation and Cisplatin Resistance in Ovarian Cancer},
journal = {Oncology Research},
year = {2026},
volume = {0},
number = {0},
pages = {1--10},
doi = {10.32604/or.2026.084046}
}
EUVIMED